Beckmann R P, Beerman T A
Grace Cancer Drug Center, Roswell Park Memorial Institute, Buffalo, New York 14263.
Mol Pharmacol. 1989 Apr;35(4):433-42.
The glucocorticoid-inducible LTL gene [Cell 38:29-38 (1984)] was used as a model target to evaluate preferential drug effects on gene expression. Specifically, the potential of bleomycin, neocarzinostatin, and actinomycin D to induce alterations in either transcriptional or posttranscriptional gene expression was assessed. A Northern blot analysis was used to measure transcriptional effects, whereas changes in posttranscriptional expression were determined through an enzymatic assay for the thymidine kinase product of the LTL gene. Comparisons of the results from these assays with results obtained from assays that evaluated drug effects on cellular RNA and protein synthesis showed that none of the drugs were capable of inducing preferential effects on transcription. However, selective drug-induced effects on the expression of thymidine kinase activity were observed.
糖皮质激素诱导的LTL基因[《细胞》38:29 - 38(1984)]被用作评估药物对基因表达的优先作用的模型靶点。具体而言，评估了博来霉素、新制癌菌素和放线菌素D在转录或转录后基因表达中诱导改变的潜力。采用Northern印迹分析来测量转录效应，而转录后表达的变化则通过对LTL基因胸苷激酶产物的酶促测定来确定。将这些测定结果与评估药物对细胞RNA和蛋白质合成影响的测定结果进行比较，结果表明，这些药物均不能诱导对转录的优先作用。然而，观察到了药物对胸苷激酶活性表达的选择性诱导作用。
